Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

46.2%

6 terminated/withdrawn out of 13 trials

Success Rate

45.5%

-41.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
7(58.3%)
Phase 2
5(41.7%)
12Total
Phase 1(7)
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT04980482Phase 2Completed

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Role: lead

NCT05960240Phase 1Completed

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Role: lead

NCT06154278Phase 2Recruiting

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Role: collaborator

NCT06277037Recruiting

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Role: lead

NCT06245291Phase 2Withdrawn

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Role: lead

NCT04820686Phase 2Terminated

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Role: collaborator

NCT04775797Phase 1Terminated

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

Role: lead

NCT02191878Phase 1Completed

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

Role: lead

NCT01262235Phase 1Completed

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Role: lead

NCT02631096Phase 2Completed

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Role: lead

NCT02041715Phase 1Terminated

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

Role: lead

NCT01518881Phase 1Terminated

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

Role: lead

NCT00927459Phase 1Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Role: lead

All 13 trials loaded